Eileen McDonnell
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,200 of the $58,458 with a category attached, or 85.9%. GSK accounts for 98.8% of it on its own, with 12 other manufacturers making up the rest. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $433.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$58K
- Boehringer Ingelheim$287
- Aurinia Pharma U.S., Inc.$101
- United Therapeutics Corporation$90
- ANI Pharmaceuticals, Inc.$55
- Astellas Pharma US Inc$34
- plus $146 from 7 others
What the payments were for
- Consulting fees$9002%
- Speaking & faculty fees$50,20086%
- Travel & lodging$4,6978%
- Food & beverage$2,6435%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 119 | $57,745 |
| Boehringer Ingelheim | 3 | $287 |
| Aurinia Pharma U.S., Inc. | 1 | $101 |
| United Therapeutics Corporation | 1 | $90 |
| ANI Pharmaceuticals, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 1 | $34 |
| Advanced Respiratory, Inc | 1 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $22 |
| AstraZeneca | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$19,623
- NUCALA$10,556
- ANORO ELLIPTA$500
- OFEV$246
- LUPKYNIS$101
How this compares
$58,458 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 299 | $3,677,829 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 509 | $412,291 |
| FasenraBenralizumab | 42 | $225,194 |
| LetairisAmbrisentan | 12 | $153,272 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $142,423 |
| NucalaMepolizumab | 27 | $100,975 |
| Spiriva RespimatTiotropium Bromide | 163 | $100,775 |
| Breo ElliptaFluticasone/Vilanterol | 197 | $96,143 |
| Dupixent SyringeDupilumab | 24 | $83,031 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $67,842 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $55,781 |
| Dupixent PenDupilumab | 11 | $40,778 |
| Incruse ElliptaUmeclidinium Bromide | 59 | $31,347 |
| EliquisApixaban | 42 | $28,482 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 734 | $26,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $287 | $3,817,629528 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $57,745 | $704,894920 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $18 | $335,372215 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $25 | $16,17913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Oaks
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.